Israel - hebraico - Ministry of Health

sam-on ltd - ferrous as fumarate; folic acid - טבליה - folic acid 400 mcg; ferrous as fumarate 100 mg - iron bivalent, oral preparations - for the prevention and treatment of iron deficiency anemia and for maintaining the level of folic acid particular in pregnancy.

Israel - hebraico - Ministry of Health

bioavenir ltd, israel - milnacipran as hydrochloride - קפסולות - milnacipran as hydrochloride 25 mg - milnacipran

Israel - hebraico - Ministry of Health

bioavenir ltd, israel - milnacipran as hydrochloride - קפסולות - milnacipran as hydrochloride 50 mg - milnacipran

Israel - hebraico - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eplerenone - טבליות מצופות פילם - eplerenone 25 mg - eplerenone

Israel - hebraico - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - eplerenone - טבליות מצופות פילם - eplerenone 50 mg - eplerenone

Israel - hebraico - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium; rilpivirine as hydrochloride - טבליות מצופות פילם - rilpivirine as hydrochloride 25 mg; dolutegravir as sodium 50 mg - dolutegravir and rilpivirine

Israel - hebraico - Ministry of Health

padagis israel agencies ltd, israel - repaglinide - טבליה - repaglinide 0.5 mg - repaglinide

Israel - hebraico - Ministry of Health

padagis israel agencies ltd, israel - repaglinide - טבליה - repaglinide 1 mg - repaglinide

Israel - hebraico - Ministry of Health

padagis israel agencies ltd, israel - repaglinide - טבליה - repaglinide 2 mg - repaglinide

Israel - hebraico - Ministry of Health

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.